Redeye: Genovis Q4 2022 - A First Sublicensing of Xork
Redeye returns with an updated take on the pick-and-shovel play Genovis following its partner Selecta Biosciences’ licensing deal with Astellas Pharma and the company’s Q4 2022 report. With reinforced confidence in the deal with Selecta, we have raised our base case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/